X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund research, clinical trials and process development and manufacturing of company's product candidates, including MORF-057, an oral small molecule inhibitor of the alpha4beta7 integrin and other programs generated from its MInT Platform.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $276.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 05, 2023
Details:
The proceeds will fund research, clinical trial and process development of Morphic’s candidates, including MORF-057, a selective, oral small molecule inhibitor of the α4β7 integrin in development to treat IBD, and other programs generated from Morphic’s MInT Platform.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2023
Details:
MORF-057 is an oral small molecule inhibitor of the α4β7 integrin, which is being investigated in adults with moderate to severe ulcerative colitis (UC).
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease. MORF-057, like vedolizumab, is designed to block the interactions between α4β7 on the surface of lymphocytes.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
MORF-057 is a selective, oral small molecule, designed to block the interactions between α4β7 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, substantially reducing lymphocyte migration from the bloodstream into intestinal mucosal tissues.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease. α4β7 has been clinically validated as a target for the treatment of IBD by the success of the approved injectable antibody therapeutic vedolizumab.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
MORF-057 is selective, oral small molecule inhibitor of α4β7 integrin for patients with IBD, 200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
MORF-057 is a potent and selective, oral small molecule inhibitor of the α4β7 integrin being studied in patients with GI disorders, holds potential for treating inflammatory bowel diseases.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
The data presented α4β7 expression of immune cells at single-cell resolution in blood and assessed the dose-dependent effect of MORF-057, small-molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease administration in nonhuman primates.
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2022
Details:
Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease (IBD).
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
